文献速递血栓与止血

免疫性血小板减少症患者大出血的管理

Management of major bleeds in patients with immune thrombocytopenia.
PubMed 文献 · J Thromb Haemost · 2020-05-06

本研究为回顾性队列研究,纳入2008至2016年四家学术医院急诊科就诊的112例免疫性血小板减少症(ITP)患者(共141次就诊),血小板<20×10^9/L且出血。其中26%患者发生大出血,危险因素包括年龄较大、男性及既往ITP治疗更多。大出血需中位3种急性治疗,死亡率10%,31%复发。

要点

  • ITP患者血小板<20×10^9/L伴出血时,26%发生大出血。
  • 大出血危险因素:年龄较大、男性、既往ITP治疗更多。
  • 大出血急性治疗常需多种联合,包括IVIG、糖皮质激素和血小板输注。

核心结论

  • ITP大出血与显著发病率和死亡率相关,口腔紫癜和血尿常为大出血前兆。

研究设计与样本

  • 回顾性队列研究,纳入2008至2016年四家学术医院急诊科就诊的112例ITP患者(共141次就诊),血小板<20×10^9/L且出血。

主要发现

  • 大出血危险因素:年龄较大(OR 1.03,95%CI 1.01-1.06)、男性(OR 3.25,95%CI 1.22-9.32)、更多既往ITP治疗(OR 1.42,95%CI 1.10-1.87)。
  • 大出血急性治疗中位需3种(IQR 2-4),包括静脉免疫球蛋白(91%就诊)、糖皮质激素(78%就诊)、血小板输注(75%就诊)。
  • 3例(10%)死亡,9例(31%)复发大出血,1例(3%)动脉血栓形成,1例(3%)永久神经功能障碍。
  • 6例患者以轻微出血就诊后中位2天(IQR 1-3)发生大出血,所有6例均有口腔紫癜,4/6有肉眼血尿。

临床怎么用

  • 对ITP患者血小板<20×10^9/L伴出血,应警惕大出血风险,尤其老年、男性及多线治疗者。
  • 口腔紫癜和血尿可能预示即将发生大出血,需密切监测。
  • 大出血常需联合IVIG、糖皮质激素和血小板输注等治疗。

局限性

  • 回顾性研究,样本量有限,大出血定义需进一步细化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A standard approach to the recognition and management of major bleeding in immune thrombocytopenia (ITP) is lacking. METHODS: Retrospective cohort study of ITP patients presenting to the emergency department (ED) with severe thrombocytopenia (platelet count <20 × 109 /L) and bleeding in four academic hospitals from 2008 to 2016. We defined a major ITP bleed as a bleed at a critical site or causing hemodynamic instability. RESULTS: We identified 112 ITP patients (n = 141 visits) who presented to the ED with platelets <20 × 109 /L and bleeding. Twenty--nine patients (26%) had 32 ED visits with major bleeds. Risk factors for major bleeds were older age (odds ratio [OR] 1.03, 95% confidence interval [CI] 1.01-1.06), male sex (OR 3.25, 95% CI 1.22-9.32), and more prior ITP therapies (OR 1.42, 95% CI 1.10-1.87). Acute treatment of major bleeds required a median of three treatments (interquartile range [IQR] 2--4), which included intravenous immune globulin (91% of visits), corticosteroids (78% of visits), and platelet transfusions (75% of visits). Three patients (10%) died, nine (31%) developed recurrent bleeds, one (3%) developed arterial thrombosis, and one (3%) had permanent neurological disability. Six patients presented with minor bleeding and subsequently developed a major bleed after a median of 2 days (IQR 1-3). All six patients had oral purpura and four of six had gross hematuria preceding the major bleed. CONCLUSIONS: Major ITP bleeds are associated with significant morbidity and mortality. Oral purpura and hematuria often preceded major bleeds. Further research is needed to refine the definition of a major ITP bleed and develop evidence-based treatment strategies.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Mithoowani S, Cervi A, Shah N, et al. Management of major bleeds in patients with immune thrombocytopenia. J Thromb Haemost. 2020. PMID: 32219982. doi:10.1111/jth.14809

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。